Primo N. Lara

A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).

David C. Smith, C. Tangen, E. Crawford, 2009, The Journal of urology.

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.

C. Tangen, C. Ryan, P. Mack, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412.

C. Ryan, H. Drabkin, T. Beer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.